If the fetal brain is harmed in any way during pregnancy, delivery or following birth, Cerebral Palsy can occur. CP is frequently accompanied by mental incapacitation, hearing loss,difficulty in speaking, lack of coordination,seizures and blindness. About 25% of instances are brought about by prenatal forces like improper nutrition, x-rays,anemia, viruses or premature delivery. About 40% of Cerebral Palsy patient diagnosis are brought on by hypoxia (the lack of oxygen) wile other causes remain idiopathic (unknown).
Physical Impairment Due to Cerebral Palsy
Children with Cerebral Palsy and Autism will likely show early signs of physical impairment. The type of physical dysfunction, location and extent of impairment varies person to person. CP can affect legs,arms or the face. CP can affect one limb, several limbs, or in some extreme cases all the limbs. Some women with autoimmune anti-phospholipid (APA) antibodies or anti-thyroid antibodies have a slightly higher risk for their children getting CP.
CP and its variants affects muscles and a childs’ ability to control them properly. Muscles can sometimes contract too little or too much. Limbs can also become stiff overtime and forced into awkward painful positions. Uneven muscle contractions can also make the patients limbs shake, writhe and/or tremble. A patient’s posture, coordination and balance are also usually affected by CP. Simple tasks such as standing up, sitting down, walking can be very difficult for some, while other patients have problems grasping objects. Other complications of Cerebral Palsy include, mental/intellectual impairment, frequent seizures, and hearing or vision or hearing impairments.
The regeneration center of Thailand takes advantage of an effective and efficient cell therapy choice for all those suffering with cerebral palsy. In contrast to conventional remedies, our stem cell protocol is much different in terms of how we target to repair the brain tissue damage itself (similar to our treatment for Alzheimer’s and MS ) and what we do differently to recover/regenerate the patients physical functions. Stem cell therapy for CP focuses on the root of the issue and not just the signs and symptoms.
Treat Cerebral Palsy With Stem Cells
Cell death and Entrapment neuropathy happen when cells are injured. These dead cells are however surrounded by both healthy and damaged cells. Gene therapy, Stem cells and exosomes have the unique capabilities to stimulate the healing of those injured cells via the secretion of cytokines. The objective of the stem cell treatment for Cerebral Palsy would be to help repair the injured cells in the immediate regions of the lesions. This targeted stimulation may result in enhanced signs and symptoms primarily physically and through movements.
The majority of patients who have received stem cell treatments for CP show improvements following the very first or sometimes second transplant. They continue to show improvement for about 6 months to 1 year. For most CP and motor neuron patients undergoing stem cell therapy, the results are permanent.
Hematopoetic Stem Cell Therapy for CP in 2024
Spastic monoplegia a type of cerebral palsy results from brain injuries. It is different from other types of CP. Monoplegia (mono = 1) causes a defect in the movement of 1 of the two limbs of the human body, usually an arm, which is either the left or the right side.
It’s extremely uncommon and numerous authorities think about it as a type of Hemiplegia with a mild connection from the other limb of the affected side of the body. Monoplegia cerebral palsy is a result of a permanent lesion within the motor cortex region from the brain which might be total or partial. Like all other kinds of cerebral palsy and SMA, the condition is sometimes irrevocable which means that there’s no opportunity of regeneration. 
Identification of CP and similar diseases like Ataxia is essentially a process of elimination since there are lots of other diseases that cause similar symptoms such as brain tumors, metabolic disorders, Erbs palsy, brachial plexus palsy, etc. Stem cell therapy for CP can offer genuine improvements for Monoplegia patients.
Types of CP Treated With Stem Cells
Treatment of Neurological Disorders
Cord blood stem cells have been especially helpful in patients with brain injuries. Cord blood derived stem cells have capability to divide and alter into neural-like stem cells. These adult stem cells have been proven to migrate towards the damaged regions, and to promote therapeutic processes, which might assist in repairing brain damage. That cord blood stem are also very responsive to the body’s immune response following an injury, by interacting directly using the organs and cells from the immune system that allow the body to repair itself.
TREATMENT PRECAUTION & RISKSPlease Note That Not All Patients Qualify for Treatment of Degenerative Neurological conditions such as Cerebral Palsy. Patients with late stage, severe underlying conditions or travel restrictions may not qualify for the 2-3 week treatment protocol in Bangkok.
CP Treatment in 2024 Overview
Total Number of Cell Treatment: will depend on patient needs
Type of Injections: Combination therapy using the childs dental pulp stem cells or Cord blood stem cells or Combination of Amniotic Membrance & Placenta derived cells are required for most cases. Our treatment uses Clinical grade stem cells which are potent & safe to administer via a Angiograph, Intravenous Drip or Intrathecally. The cell infusions are non-surgical, minimally invasive and will not require extended hospital stays.
Physical Rehabilitation Post-Treatment: Physical Rehabilitation therapy is optional depending on the patients’ travel/time constraints. Complete physical rehabilitation post-therapy and can be provided upon request for 2-5 hours per day and up to 6 days per week.
Medical visas and extended stay accommodations for the patients and family can also be included upon request.
Treatment Guidelines for Cerebral Palsy
Cell Therapy for CP using a combination of neural progenitor and mesenchymal stem cells will require a minimum of 14-21 nights in Bangkok. Due to the varying degrees of existing medical conditions and the stage of degeneration, our neurological stem cell team will need to review the potential candidate medical condition before a detailed treatment protocol can be provided. Upon approval, a detailed treatment plan will be provided that will include the specifics such as the day by day medical treatment outline with exact total number nights required along with the total medical related costs (excluding accommodations or flights). To begin the qualification process for our multi-stage Treatment protocol please prepare your recent medical records such as Genetic tests for MS, Brain MRI’s,CT Scans or PET Scans (Preferred ) and contact us today.
Published Clinical Citations
 ^ Wang, Xiaodong, Hezhen Hu, Rongrong Hua, Jing Yang, Pei Zheng, Xinxin Niu, Hongbin Cheng, et al. 2015. Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors. Cytotherapy, no. 2. doi:10.1016/j.jcyt.2014.09.010. https://www.ncbi.nlm.nih.gov/pubmed/25593078
 ^ Keeratisiroj, Orawan, Nuanlaor Thawinchai, Wantana Siritaratiwat, and Montana Buntragulpoontawee. 2015. Prognostic Predictors for Ambulation in Thai Children With Cerebral Palsy Aged 2 to 18 Years. Journal of child neurology, no. 13 (April 28). doi:10.1177/0883073815582267. https://www.ncbi.nlm.nih.gov/pubmed/25922262
 ^ Kułak-Bejda, Agnieszka, Piotr Kułak, Grzegorz Bejda, Elżbieta Krajewska-Kułak, and Wojciech Kułak. 2016. Stem cells therapy in cerebral palsy: A systematic review. Brain & development, no. 8 (April 20). doi:10.1016/j.braindev.2016.03.002. https://www.ncbi.nlm.nih.gov/pubmed/27004672
 ^ Kumban, Wannisa, Sugalya Amatachaya, Alongkot Emasithi, and Wantana Siritaratiwat. 2013. Effects of task-specific training on functional ability in children with mild to moderate cerebral palsy. Developmental neurorehabilitation, no. 6 (March 11). doi:10.3109/17518423.2013.772672. https://www.ncbi.nlm.nih.gov/pubmed/23477366